Figure 2.
Rhabdomyosarcoma survival. Kaplan-Meier overall survival (OS) curves for patients with rhabdomyosarcoma (RMS) by age group (A), patients <16 years: N=118 patients, N at 5 years=51, patients ≥16 years: N=50 patients, N at 5 years=7; by histological subtype (B), embryonal RMS: N=102 patients, N at 5 years=41, botryoid RMS: N=15 patients, N at 5 years=8, and alveolar RMS: N=51 patients, N at 5 years=9; by age group for embryonal RMS (C), patients <16 years: N=78 patients, N at 5 years=36, patients ≥16 years: N=24 patients, N at 5 years=5; by age group for alveolar RMS (D), patients <16 years: N=26 patients, N at 5 years=7, patients ≥16 years: N=25 patients, N at 5 years=2; for non-metastatic embryonal RMS, non-metastatic alveolar RMS and metastatic embryonal and alveolar RMS (E), non-metastatic embryonal RMS: N=90 patients, N at 5 years 40, non-metastatic alveolar RMS: N=27 patients, N at 5 years=8, metastatic embryonal and alveolar RMS: N=35 patients, N at 5 years=2; and by age group for non-metastatic embryonal (F), patients <16 years at diagnosis: N=72 patients, N at 5 years=36, patients ≥16 years at diagnosis: N=18 patients, N at 5 years=4.